J. Psychiatry 2010, 196, 36–40. 13. Knezovic, A.; Osmanovic-Barilar, J.; Curlin, M.; Hof, P.R. ; Šimić, G.; Riederer, P.; Salkovic-Petrisic, M. et al. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimers disease. J. Neural Transm. 2015, 122, 577–592. 14. Sharma, M. et al. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 2001, 68, 1021–1029. 15. Latina, V. et al., Tau Cleavage Contributes to Cognitive Dysfunction in Streptozotocin-Induced Sporadic Alzheimers Disease (sAD) Mouse Model. Int. J. Mol. Sci. 2021, 22, 12158. https://doi.org/10.3390/ijms222212158. External links
U.S. Patent 3,027,300
FDA drug details
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.Susoctocog alfa was approved for medical use in the United States in October 2014, and for medical use in the European Union in November 2015.Factor VIII is one of the proteins needed for normal clotting of the blood. References
External links
"Susoctocog alfa". Drug Information Portal. U.S. National Library of Medicine.